Saratin
Anti-platelet adhesion protein blocking collagen-mediated platelet activation.
- Hementerin80 kDa
- Hementin80 kDa
- Hementin-Like Protein (HLP-1)80 kDa
- Leech Collagenase70 kDa
- Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
- Leech Apyrase67 kDa
- Calin65 kDa
- Hyaluronidase60 kDa
- Antithrombin III binding protein58 kDa
- Collagenolytic Fibrinolysin55 kDa
- Leech Thrombospondin-Like Protein50 kDa
- Saratin12 kDa
Mechanistic Evidence Box
Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.- Page type
- Compound profile
- Evidence type
- Preclinical / biochemical characterization
- Evidence level
- In vitro
- Drug vs leech
- Purified natural compound
- Safety domains
- Bleeding
Clinical translation limit
Saratin's in vitro inhibition of platelet adhesion does not establish clinical efficacy. No FDA-approved derivative exists. Mechanism is preclinical/biochemical only and does NOT establish efficacy of whole medicinal-leech therapy.
Molecular Profile
- Category
- Antiplatelet
- Evidence tier
- Preclinical
- Molecular weight
- 12,000 Da
- Source species
- Hirudo medicinalis
- Discovered
- 2001 · Barnes et al.
Biological Targets
- → collagen (GPVI-mediated platelet adhesion)
Key Citations
- Barnes CS et al. (2001), Sem Thromb Hemost
External Resources
Related Antiplatelet Compounds
Calin
Anti-platelet adhesion protein that blocks von Willebrand factor–collagen binding.
Decorsin
RGD-containing peptide that inhibits the platelet GP IIb/IIIa receptor; the drug eptifibatide was modelled on snake-venom barbourin, not on decorsin.
Ornatin
RGD-peptide GP IIb/IIIa antagonist — sister molecule to decorsin from a different leech species.
Eptifibatide
Cyclic heptapeptide GP IIb/IIIa receptor antagonist — FDA approved 1998. Designed from snake-venom barbourin; not derived from the leech.